Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
| Revenue (TTM) | $3.58B |
| Gross Profit (TTM) | $1.81B |
| EBITDA | $506.00M |
| Operating Margin | 4.55% |
| Return on Equity | -8.62% |
| Return on Assets | 1.93% |
| Revenue/Share (TTM) | $17.91 |
| Book Value | $6.80 |
| Price-to-Book | 1.48 |
| Price-to-Sales (TTM) | 0.53 |
| EV/Revenue | 1.119 |
| EV/EBITDA | 43.84 |
| Quarterly Earnings Growth (YoY) | 15.20% |
| Quarterly Revenue Growth (YoY) | -7.50% |
| Shares Outstanding | $199.35M |
| Float | $187.72M |
| % Insiders | 0.65% |
| % Institutions | 117.38% |
Volatility is currently expanding
DENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
News Summary Q3 2026 net sales of $836 million Q3 2026 GAAP gross margin of 52.9% , GAAP diluted loss per share of ($0.01) Q3 2026 adjusted gross margin of 54.5% , adjusted EBITDA margin of 17.3% , adjusted EPS of $0.29 Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™ portfolio with the launch of the Surity ™ Urinary Management System Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.
DENTSPLY SIRONA faces Q3 earnings pressure from weak dental demand, tariff costs and segment challenges, while Wellspect's growth may offer some relief.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CHARLOTTE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to review its third quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call.
XRAY expands its U.S. distribution reach through Midwest Dental, aiming to boost digital dentistry adoption and broaden access to its technology portfolio.
MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology. The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology.
XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XRAY and any ticker you trade — then tracks every position and per-strategy win rate.
